Published online Dec 15, 2020. doi: 10.4251/wjgo.v12.i12.1443
Peer-review started: August 5, 2020
First decision: September 24, 2020
Revised: September 28, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: December 15, 2020
Processing time: 127 Days and 4.2 Hours
Neoadjuvant therapy significantly reduces the number of yielded lymph nodes (LNs) for rectal cancer, and the number of dissected LNs in rectal cancer after neoadjuvant therapy has a controversial effect on the prognosis.
Studies have shown that the number of LNs after rectal cancer is significantly reduced after neoadjuvant therapy. Some scholars have found that less than 12 LNs in rectal cancer patients receiving neoadjuvant radiotherapy should be considered as a better prognostic factor. However, others believe that dissecting at least 12 LNs is an independent and favorable prognostic factors for rectal cancer after neoadjuvant therapy. Therefore, it is necessary to conduct a meta-analysis to systematically and comprehensively study the influence of the number of LNs retrieved after neoadjuvant treatment on the survival outcome of patients with rectal cancer.
To evaluate the effect of LN production in rectal cancer after neoadjuvant treatment on survival through meta-analysis.
The meta-analysis methods were adopted to realize the objectives.
Nine articles were included in the meta-analyses. Statistical analysis revealed a statistically significant difference in overall survival (OS) [hazard ratio (HR) = 0.76, 95% confidence interval (CI) = 0.66-0.88, I2 = 12.2%, P = 0.336], disease-free survival (DFS) (HR = 0.76, 95%CI: 0.63-0.92, I2 = 68.4%, P = 0.013), and distant recurrence (DR) (HR = 0.63, 95%CI: 0.48-0.93, I2 = 30.5%, P = 0.237) between the LNs ≥ 12 and LNs < 12 groups, but local recurrence (HR = 0.67, 95%CI: 0.38-1.16, I2 = 0%, P = 0.348) showed no statistical difference. Moreover, subgroup analysis of LN negative patients revealed a statistically significant difference in DFS (HR = 0.67, 0.95%CI: 0.52-0.88, I2 = 0%, P = 0.565) between the LNs ≥ 12 and LNs < 12 groups.
This meta-analysis confirmed that dissecting at least 12 LNs after neoadjuvant therapy may improve the patients’ OS, DFS, and DR.
Some limitations in this analysis should be handled carefully. The most important limitation is that the included studies are all retrospective. Because some potential deviations are difficult to adjust, further careful design and large-scale randomized controlled trial experiments are needed to determine the effect of the number of anatomical LNs on the prognosis of rectal cancer after neoadjuvant treatment. In addition, because neoadjuvant therapy reduces LN yield, further research is needed on the impact of different LN numbers on prognosis, such as 6 LNs, 7 LNs, and 8 LNs.